Release Date: 23-Jan-2025
Silevimig (GR1801) is a novel bispecific antibody developed by Shanghai Genrix Biopharmaceuticals, designed as a therapeutic agent for rabies. This human bispecific antibody combines two monoclonal antibodies, A2 and B353, which target distinct epitopes on the rabies virus (RABV). The primary aim of GR1801 is to provide a more effective treatment by targeting multiple sites on the virus, enhancing neutralization capabilities and improving the therapeutic outcome for patients exposed to rabies.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
GR1801 is an asymmetric immunoglobulin G1 (IgG1) molecule, a feature that sets it apart from traditional antibody formats. One arm of the antibody is in a fragment antigen-binding (Fab) form, with the A2 monoclonal antibody targeting epitope III on the rabies virus. The other arm is a single-chain variable fragment (scFv), with the B353 monoclonal antibody targeting epitope I. This unique design allows for more efficient binding to the virus and enhances the neutralization of rabies. The molecule is constructed using Knobs-into-Holes technology, a cutting-edge approach that improves the stability and functionality of bispecific antibodies.
The development of GR1801 holds significant promise for rabies treatment, a disease with a high mortality rate once clinical symptoms appear. By targeting two distinct epitopes, Silevimig aims to provide a more potent and broad-spectrum response to rabies virus infection, offering an alternative to current rabies treatments. This bispecific antibody approach may also potentially reduce the risk of resistance by engaging different sites on the virus simultaneously.
Currently, GR1801 is undergoing Phase 3 clinical trials in China, evaluating its safety and efficacy as a therapeutic for rabies exposure. If successful, Silevimig could become an important addition to the arsenal of treatments for rabies, significantly improving outcomes for patients at risk of developing the fatal disease.